| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NANOGP8 |
| Uniprot No | Q6NSW7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-305aa |
| 氨基酸序列 | MSVDPACPQS LPCFEASDCK ESSPMPVICG PEENYPSLQM SSAEMPHTET VSPLPSSMDL LIQDSPDSST SPKGKQPTSA ENSVAKKEDK VPVKKQKTRT VFSSTQLCVL NDRFQRQKYL SLQQMQELSN ILNLSYKQVK TWFQNQRMKS KRWQKNNWPK NSNGVTQKAS APTYPSLYSS YHQGCLVNPT GNLPMWSNQT WNNSTWSNQT QNIQSWSNHS WNTQTWCTQS WNNQAWNSPF YNCGEESLQS CMHFQPNSPA SDLEAALEAA GEGLNVIQQT TRYFSTPQTM DLFLNYSMNM QPEDV |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NANOGP8重组蛋白的3篇参考文献的简要信息：
1. **"NANOGP8 is a retrogene expressed in cancers"**
*作者：Jeter, C.R. et al.*
摘要：研究揭示了NANOGP8作为NANOG假基因在多种癌症中的异常激活，并通过重组蛋白实验证明其促进肿瘤干细胞自我更新和化疗耐药性的功能。
2. **"NANOGP8 regulates stem cell-like properties in hepatocellular carcinoma"**
*作者：Zhang, X. et al.*
摘要：通过构建NANOGP8重组蛋白表达模型，研究发现其通过激活Wnt/β-catenin通路增强肝癌细胞干性，促进肿瘤转移和复发。
3. **"The role of NANOGP8 in colorectal cancer chemoresistance"**
*作者：Liu, Y. et al.*
摘要：利用重组NANOGP8蛋白进行功能研究，发现其通过调控ABC转运蛋白表达，介导结直肠癌细胞对5-FU的耐药性，为靶向治疗提供依据。
注：以上文献信息为示例，实际研究中建议通过PubMed或Web of Science以关键词“NANOGP8 recombinant protein”检索最新文献。
**Background of NANOGP8 Recombinant Protein**
NANOGP8 is a homolog of the NANOG gene, a critical transcription factor in maintaining pluripotency and self-renewal in embryonic stem cells. Unlike the canonical NANOG, which is predominantly expressed in undifferentiated cells, NANOGP8 is a retrogene derived from ancestral mRNA reverse transcription and integration into the genome. It shares high sequence similarity with NANOG but is classified as a pseudogene due to evolutionary mutations. However, emerging studies reveal that NANOGP8 is epigenetically reactivated in certain cancers, where it contributes to tumorigenesis, stemness, and therapy resistance.
The recombinant NANOGP8 protein is engineered to study its functional role in cellular reprogramming and cancer biology. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant protein retains the DNA-binding domain and transcriptional activity of NANOG, enabling researchers to explore its interactions with pluripotency-associated pathways, such as Wnt, STAT3. and Notch. Its aberrant expression in cancers, particularly in tumor-initiating cells, correlates with poor prognosis, metastasis, and chemoresistance, making it a potential therapeutic target.
Research applications include elucidating mechanisms of cancer stem cell maintenance, epithelial-mesenchymal transition (EMT), and tumor microenvironment interactions. The recombinant protein is also used to develop antibodies or inhibitors targeting NANOGP8-driven oncogenic pathways. Additionally, its role in cellular plasticity and dedifferentiation highlights its relevance in regenerative medicine and disease modeling.
Overall, NANOGP8 recombinant protein serves as a vital tool to dissect the duality of NANOG family members in development and disease, bridging gaps between stem cell biology and oncology.
×
